Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cannabidiol oral solution for epilepsy with myoclonic-atonic seizures in children and adolescents
2021-003094-61Phase 3Terminated
- Sponsor
- GW Pharmaceuticals
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in myoclonic astatic epilepsy (MAE) comparing Cannabidiol oral solution with Placebo (2 arms). Started May 2022; status: terminated.
02
Drugs
cannabidiol
03
Conditions
myoclonic astatic epilepsy (MAE)
Beyond the preview
Go deeper on 2021-003094-61.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003094-61.